GlassScriptPhysician profile
Adaobi C Kanu
NPI 1518905934
$4,492.18
in general payments reported to CMS, 2019-2025
28 companies · $840 in 2025
The $840 reported for 2025 was more than what 85% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $205 · 2021: $466 · 2022: $915 · 2023: $753 · 2024: $838 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.73 |
| Education | $364.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $864.71 | 2019-2025 | Fasenra, Tezspire |
| Vertex Pharmaceuticals Incorporated | $567.80 | 2019-2025 | Trikafta |
| Amgen INC. | $476.08 | 2021-2025 | Tezspire |
| Chiesi USA, INC. | $435.98 | 2019-2023 | Bronchitol |
| Genzyme Corporation | $359.62 | 2019-2025 | |
| Mylan Specialty L.P. | $210.41 | 2020-2024 | Tobi Podhaler |
| Genentech USA, INC. | $197.04 | 2022-2025 | Xolair |
| Gilead Sciences, INC. | $181.92 | 2019-2022 | |
| Insmed, INC. | $149.68 | 2023-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $144.72 | 2020-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $136.09 | 2023-2024 | Dupixent |
| Abbvie INC. | $118.82 | 2022-2025 | |
| Ars Pharmaceuticals Operations, INC. | $117.29 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Philips North America LLC | $94.36 | 2020-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $52.88 | 2019-2020 | |
| Advanced Respiratory, INC | $51.45 | 2019-2020 | |
| Alcresta Therapeutics, INC. | $27.40 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.26 | 2021 | |
| Viatris Specialty LLC | $24.74 | 2025 | Tobi Podhaler |
| Electromed, INC. | $24.36 | 2025 | Smartvest |
| Tandem Diabetes Care, INC. | $22.32 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi US Services INC. | $21.08 | 2025 | |
| Vivus LLC | $20.86 | 2022 | |
| Baxter Healthcare | $20.38 | 2022 | |
| Aimmune Therapeutics, INC. | $16.84 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $15.36 | 2025 | Vaxneuvance, M-M-R II, Gardasil 9 |
| Supernus Pharmaceuticals, INC. | $14.78 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adaobi Kanu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.